Immune Cells, If Rendered Insensitive to Transforming Growth Factor-Beta, Can Cure Prostate Cancer

Abstract

The objective of the current proposal is to perform immunotherapy to eradicate prostate cancer and at the same time to avoid the development of autoimmune disease. The proposal contains two tasks. The first task is a combination of TGF-beta insensitive tumor-reactive T cell adoptive therapy for the treatment of mouse prostate cancer. The second task is an inducible TGF-beta based gene therapy. At the time of this report, we have completed Task 1 and a paper has been published (Cancer Research 65:l76l-l769, 2005; Prostate 66:235-247, 2005) . Currently, we have modified approaches for studies described in Task 2. Instead of using the tetracycline-inducible system, we have adapted a herpes simplex thymidine kinase/ganciclovir system, which is working successfully and is in the final phase of completing the task.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 2006
Accession Number
ADA447657

Entities

People

  • Chung Lee

Organizations

  • Northwestern University

Tags

DTIC Thesaurus Topics

  • Anti-Bacterial Agents
  • Autoimmune Diseases
  • Blood
  • Cell Line
  • Cells
  • Chemistry
  • Gene Therapy
  • Growth Factors
  • Health Services
  • Lymphatic System
  • Lymphocytes
  • Peptide Growth Factors
  • Peptides
  • Prostate Cancer
  • Proteins
  • Tissues

Fields of Study

  • Biology
  • Medicine

Readers

  • Oncology (Cancer Research).
  • Team-Based Human-Centered Cognitive Task Decision Making and Information Performance.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech